Last $15.51 USD
Change Today +0.14 / 0.91%
Volume 424.8K
ANAC On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

anacor pharmaceuticals inc (ANAC) Key Developments

Anacor Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial of AN2728 in Mild-To-Moderate Atopic Dermatitis

Anacor Pharmaceuticals announced that the first patient has been enrolled in the Phase 3 trial of AN2728, a novel boron-based phosphodiesterase-4 (PDE-4) inhibitor, for the topical treatment of mild-to-moderate atopic dermatitis. Atopic dermatitis is a chronic rash characterized by inflammation and itch and affects approximately 10% - 20% of infants and young children. The Phase 3 trial consists of two multi-center, double-blind, vehicle-controlled studies which will enroll approximately 750 subjects per study who will be randomized 2:1 (active:vehicle). Both studies will be conducted at multiple sites and enroll subjects ages two years and older with mild-to-moderate atopic dermatitis, defined as an Investigator Static Global Assessment (ISGA) score of 2 ('mild') or 3 ('moderate'). The ISGA is a 5-point scale from 0 to 4. AN2728 Ointment, 2% will be applied twice daily for 28 days. The primary efficacy endpoint will be treatment success at Day 29, defined as an ISGA of 'Clear' or 'Almost Clear' with at least a 2-grade improvement from baseline. Secondary endpoints will include an ISGA of 'Clear' or 'Almost Clear' at Day 29 as well as time to treatment success. Safety evaluation will include reported adverse events, safety laboratory tests, and vital signs. Subjects who complete either Phase 3 study will have the option to enroll in a long-term safety trial to evaluate the safety of intermittent use of AN2728 Ointment, 2% for up to 12 months. At least 100 subjects will be enrolled for 12 months and at least 300 subjects will be enrolled for 6 months, during which time subjects will be treated as needed under the direction of the investigator.

Anacor Pharmaceuticals, Inc. Announces Executive Changes

Anacor Pharmaceuticals, Inc. announced that the company's Board of Directors has appointed Paul L. Berns, Anacor's Chairman of the Board of Directors, to assume the role of President and Chief Executive Officer, effective immediately. Mr. Berns succeeds David P. Perry who has served as Anacor's President and Chief Executive Officer since 2002. Mr. Berns has over 20 years of industry experience as an executive in biotechnology and pharmaceutical companies. He most recently served as the President and Chief Executive Officer of Allos Therapeutics prior to its acquisition by Spectrum Pharmaceuticals, Inc. in 2012.

Anacor Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013

Anacor Pharmaceuticals, Inc. reported unaudited earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported total revenues of $8,485,000 against $3,288,000 for the same period in the last year. Income from operations was $134,150,000 against loss from operations of $11,473,000 for the same period in the last year. Income before provision for income taxes was $132,454,000 against loss before provision for income taxes of $12,476,000 a year ago. Net income was $130,748,000 or $3.01 per diluted common share against net loss of $12,476,000 or $0.36 per basic and diluted common share for the same period in the last year. The increase revenue was primarily due to the recognition of the remaining $4.8 million of deferred revenue under the Medicis agreement as a result of the termination of that agreement in October 2013. For the year, the company reported total revenues of $17,288,000 against $10,740,000 for the same period in the last year. Income from operations was $92,517,000 against loss from operations of $53,192,000 for the same period in the last year. Income before provision for income taxes was $86,471,000 against loss before provision for income taxes of $56,087,000 a year ago. Net income was $84,765,000 or $2.10 per basic and diluted common share against net loss of $56,087,000 or $1.76 per basic and diluted common share for the same period in the last year. The increase in Revenue was primarily due to research work performed under agreements with the Gates Foundation and DTRA and the recognition of the remaining deferred revenue under the Medicis agreement.

Anacor Pharmaceuticals Announces Appointment of Vince Ippolito as Executive Vice President and Chief Commercial Officer

Anacor Pharmaceuticals announced the appointment of Vince Ippolito as Executive Vice President and Chief Commercial Officer. Mr. Ippolito has over 25 years of experience leading specialty medical sales and marketing efforts at Valeant Pharmaceuticals, Inc. (Valeant), Medicis Pharmaceutical Corporation (Medicis) and Novartis AG. Mr. Ippolito recently served as Senior Vice President, General Manager, Aesthetics at Valeant following its acquisition of Medicis in December 2012. Mr. Ippolito joined Medicis in 2003 as General Manager of Dermatology products, and in 2006, he became Senior Vice President of North American Sales. In 2008, he became Executive Vice President, Sales and Marketing and served in that role until Medicis was acquired. During his tenure at Medicis, he helped launch more than ten new products, including LOPROX(R) Shampoo, VANOS(R), Restylane(R), Perlane(R), SOLODYN(R), ZIANA(R) and DYSPORT(R). Prior to joining Medicis, Mr. Ippolito was employed by Novartis AG from 1986 to 2002, where he served in a variety of sales and marketing roles, including General Manager, Marketing Group Brand Leader for Dermatology and Bone Products where he led the re-launch of Lamisil(R), and Vice President of Respiratory, Dermatology and Pediatric sales where he oversaw the launch of four new products including Elidel(R).

Anacor Pharmaceuticals, Inc., Q4 2013 Earnings Call, Mar 13, 2014

Anacor Pharmaceuticals, Inc., Q4 2013 Earnings Call, Mar 13, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANAC:US $15.51 USD +0.14

ANAC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ANAC.
View Industry Companies
 

Industry Analysis

ANAC

Industry Average

Valuation ANAC Industry Range
Price/Earnings 7.4x
Price/Sales 36.9x
Price/Book 5.3x
Price/Cash Flow 7.7x
TEV/Sales 27.3x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANACOR PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.